Immune Response Biopharma, Inc. (c) 2010-2020


Press Releases TM

Immune Response BioPharma, Inc. Provides Update on Remune HIV Vaccine Development: IRBP Expects the FDA to Accept the Remune Pediatric Indication BLA Filing. IRBP Expects Remune for pediatric to be its first approved indication. The FDA OOPD supports the HIV vaccine for children and has designated Remune FDA Orphan drug status, and data verified by NCI lead investigator verfies Remune is safe and effective for pediatric use, Given the design challenges of further pediatric HIV studies feasibility, sufficient data is on hand to garner approval. IRBP is currently addressing technical aspects of the Remune pediatric BLA to ensure a complete application submission, all study line data generated has been processed and analyzed and formatted in eCTD format. IRBP expects acceptance by Q1 2020. a PDUFA Target Date of late 2020 to coincide with manufacturing of new commercial vaccine batches. The Remune BLA PDUFA filing fee is waived for the Remune pediatric indication as an FDA Orphan Designated treatment on Feb 14th 2014 Remune was granted the FDA Orphan drug status endorsement.

October 30th 2019


Immune Response BioPharma, Inc. Declares Q1 Dividend of a Minimum $100 per shareholder of Record Feb 1st Payable Feb 15th 2020

October 30th 2019


Immune Response BioPharma, Inc. Declares Q4 Dividend of a Minimum $100 per Shareholder of Record December 14th Payable on December 25th 2019

June 3rd 2019


Immune Response BioPharma, Inc. Declares Dividend Payable September 14th of $100 Dividend per Shareholder of Record  September 1st 2019

May 24th 2019








                        Immune Response BioPharma, Inc.TM Copyright (C) 2010-2020  All Rights Reserved